Safety and Tolerability of Bexmarilimab Plus Pembrolizumab for Patients With Advanced (Inoperable or Metastatic) Non-small Cell Lung Cancer (NSCLC)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 24 Jul 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

18 Jul 2023 Status changed from not yet recruiting to withdrawn prior to enrolment. The study was inactivated with the IRB on May 15, 2023. The sponsor notified the PI that a Phase II trial had been allowed to proceed by the FDA.
20 Apr 2023 Planned initiation date changed from 1 Mar 2023 to 1 Jun 2023.
27 Jan 2023 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com